HAOHAI BIOTEC (06826) announced on December 12, 2025, that the company and Zhong Xiaoyan intend to acquire approximately 19.8% and 2.4554% equity stakes, respectively, in Jiangxi Ruiji Bioengineering Co., Ltd. The transaction amounts to approximately RMB 38.3515 million and RMB 4.756 million, respectively.

The target company's products are primarily used in orthopedic and ophthalmic applications, including tendon injury repair, ocular surface burns, wound and lesion repair, as well as implantation and support post-lacrimal duct obstruction probing.

By investing in the target company and securing its product distribution rights in China, HAOHAI BIOTEC will enter the high-value-added medical device market for biological amniotic membranes. This move complements the group's existing product portfolio and expands its business presence in orthopedics and ophthalmology.

Additionally, the target company's amniotic membrane materials, which possess human-derived biological properties, provide critical technology and material foundations for the group in regenerative medicine and tissue engineering. This acquisition is expected to drive future product innovation and technological advancements.